Akari Therapeutics, Plc Income Tax Expense
Akari Therapeutics, Plc (AKTX) reported Income Tax Expense of -$859.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxExpenseBenefit · last filed 2026-08-13
- Akari Therapeutics, Plc income tax expense (benefit) for the quarter ending 2026-06-30 was $0.00.
- Akari Therapeutics, Plc income tax expense (benefit) for the quarter ending 2026-03-31 was -$859.00K.
- Akari Therapeutics, Plc income tax expense (benefit) for the quarter ending 2025-12-31 was $85.00K.
- Akari Therapeutics, Plc income tax expense (benefit) for the quarter ending 2025-09-30 was -$1.09M.
- Akari Therapeutics, Plc income tax expense (benefit) for fiscal 2025 was -$1.00M.
- Akari Therapeutics, Plc income tax expense (benefit) for fiscal 2024 was $0.00.
- Akari Therapeutics, Plc income tax expense (benefit) for fiscal 2023 was $0.00.
| Period end | Income Tax Expense (Benefit) 3 month | Income Tax Expense (Benefit) 3 month as first filed | Income Tax Expense (Benefit) 6 month | Income Tax Expense (Benefit) 9 month | Income Tax Expense (Benefit) 12 month | Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$859.00K 10-Q · filed 2026-08-13 | -$774.00K derived: sum of 3 quarters · filed 2026-08-13 | -$1.86M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2026-03-31 | -$859.00K 10-Q · filed 2026-05-19 | -$774.00K derived: sum of 2 quarters · filed 2026-05-19 | -$1.86M derived: sum of 3 quarters · filed 2026-05-19 | -$1.86M derived: sum of 4 quarters · filed 2026-05-19 | ||
| 2025-12-31 | $85.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$1.00M derived: sum of 2 quarters · filed 2026-03-30 | -$1.00M derived: sum of 3 quarters · filed 2026-03-30 | -$1.00M 10-K · filed 2026-03-30 | ||
| 2025-09-30 | -$1.09M 10-Q · filed 2025-11-13 | -$1.09M derived: sum of 2 quarters · filed 2025-11-13 | -$1.09M 10-Q · filed 2025-11-13 | |||
| 2025-06-30 | $0.00 10-Q · filed 2025-08-13 | $0.00 10-Q · filed 2025-08-13 | ||||
| 2025-03-31 | $0.00 10-Q · filed 2025-05-14 | |||||
| 2024-12-31 | $0.00 10-K · filed 2025-04-15 | |||||
| 2024-06-30 | $0.00 8-K · filed 2024-09-06 | $0.00 8-K · filed 2024-09-06 | ||||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-14 | |||||
| 2023-12-31 | $0.00 10-K · filed 2025-04-15 | |||||
| 2023-06-30 | $0.00 8-K · filed 2024-09-06 | $0.00 8-K · filed 2024-09-06 | ||||
| 2022-12-31 | -$74.00K 8-K · filed 2024-09-06 | $0.00 20-F · filed 2023-05-01 | ||||
| 2021-12-31 | $0.00 20-F · filed 2023-05-01 | |||||
| 2020-12-31 | $0.00 20-F · filed 2023-05-01 | |||||
| 2019-12-31 | $0.00 20-F · filed 2022-05-16 | |||||
| 2018-12-31 | $0.00 20-F · filed 2021-04-21 | |||||
| 2017-12-31 | $0.00 20-F · filed 2020-03-31 | |||||
| 2016-12-31 | $0.00 20-F · filed 2019-04-23 | |||||
| 2016-03-31 | $0.00 10-Q · filed 2016-05-12 | $0.00 derived: sum of 2 quarters · filed 2018-07-18 | $0.00 derived: sum of 3 quarters · filed 2018-07-18 | $0.00 derived: sum of 4 quarters · filed 2018-07-18 | ||
| 2015-12-31 | $0.00 derived: 20-F 12 month − 10-Q 9 month · filed 2018-07-18 | $0.00 derived: sum of 2 quarters · filed 2018-07-18 | $0.00 derived: sum of 3 quarters · filed 2018-07-18 | $0.00 20-F · filed 2018-07-18 | ||
| 2015-09-30 | $0.00 10-Q · filed 2015-11-23 | $0.00 derived: sum of 2 quarters · filed 2015-11-23 | $0.00 10-Q · filed 2015-11-23 | $0.00 derived: sum of 4 quarters · filed 2017-03-31 | ||
| 2015-06-30 | $0.00 10-Q · filed 2015-08-12 | -$560.00K 10-Q · filed 2015-08-12 | $0.00 derived: sum of 3 quarters · filed 2017-03-31 | $0.00 derived: sum of 4 quarters · filed 2017-03-31 | ||
| 2015-03-31 | $0.00 10-Q · filed 2016-05-12 | -$560.00K 10-Q · filed 2015-05-12 | $0.00 derived: sum of 2 quarters · filed 2017-03-31 | $0.00 derived: sum of 3 quarters · filed 2017-03-31 | $0.00 derived: sum of 4 quarters · filed 2017-03-31 | |
| 2014-12-31 | $0.00 derived: 20-F 12 month − 10-Q 9 month · filed 2017-03-31 | $0.00 derived: sum of 2 quarters · filed 2017-03-31 | $0.00 derived: sum of 3 quarters · filed 2017-03-31 | $0.00 20-F · filed 2017-03-31 | ||
| 2014-09-30 | $0.00 10-Q · filed 2015-11-23 | $0.00 derived: sum of 2 quarters · filed 2015-11-23 | $0.00 10-Q · filed 2015-11-23 | |||
| 2014-06-30 | $0.00 10-Q · filed 2015-08-12 | $0.00 10-Q · filed 2015-08-12 | ||||
| 2014-03-31 | $0.00 10-Q · filed 2015-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |